洛铂联合氟尿嘧啶新辅助化疗治疗宫颈癌68例  

Clinical Observation of the Neoadjuvant Chemotherapy with Lobaplatin and 5-fluorouracil in Treatment for Cervical Cancer

作　　者：刘志杰[1] 周军[1] 李妍芹[1] 

机构地区：[1]甘肃兰州军区兰州总医院妇产科,兰州730050

出　　处：《中国中医药现代远程教育》2012年第5期143-144,共2页Chinese Medicine Modern Distance Education of China

摘　　要：目的探讨洛铂联合氟尿嘧啶新辅助化疗对宫颈癌的疗效及安全性。方法选择病理确诊的68例Ⅰb-Ⅱb期宫颈癌患者,术前行洛铂联合氟尿嘧啶1～2个疗程,化疗后行宫颈癌根治术。结果新辅助化疗临床有效率达100%,副反应较轻,患者和医护人员的接受性更好。结论术前洛铂联合氟尿嘧啶新辅助化疗可使Ⅰb-Ⅱb期宫颈癌患者临床分期降低,提高手术成功率,值得推广。Objective To observe curative efficacy and safety on treating cervical cancer with Lobaplatin and 5-fluorouracil. Methods 68 cases of Ⅰ b- Ⅱ b period cervical cancer were treated by using the Lobaplatin and 5-fluorouracil regimen for 1-2 cycles before operation of radical hysterectomy. Results After the neoadjuvant chemotherapy（NACT）,the therapeutic effective rate can obtain 100%,the toxic reaction was lighter, there was a better acceptability for both patients and medical personnel. Conclusions Clinical staging of I b- lIb period cervical cancer can be depressed by untied chemotherapy of before operation, at the same time, the successful rate of operation can be raised.

关 键 词：宫颈癌 新辅助化疗 洛铂 氟尿嘧啶 中医病因 

分 类 号：R737.33[医药卫生—肿瘤]